Second Line Breast Cancer Trial
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced Breast Cancer
Interventions: DRUG: Fulvestrant|DRUG: Anastrozole|DRUG: Fulvestrant
Sponsor: AstraZeneca